TREX1, a predator for treating MSI‐H tumors?
Immunotherapy benefits many patients; yet, some with MSI‐H tumors remain unresponsive despite their high immunogenicity. Xu et al. reveal that TREX1 enables immune evasion by degrading cytosolic DNA and suppressing cGAS–STING–IFN‐I signaling. TREX1 loss restores DNA sensing, increases CD8+ T and NK cell infiltration, and boosts antitumor immunity ...
Elena Benidovskaya +2 more
wiley +1 more source
Residue-Resolved Liquid-State Hyperpolarized NMR of Peptide Condensate Surfaces. [PDF]
Brandis D +3 more
europepmc +1 more source
Does mechanical screening improve fuel properties? Effects of mechanical screening of stored logging residue chips on ash chemistry and other parameters relevant for combustion [PDF]
Marjan Bozaghian +7 more
openalex
The LINC01116 long noncoding RNA is induced by hypoxia and associated with poor prognosis and high recurrence rates in two cohorts of lung adenocarcinoma patients. Here, we demonstrate that besides its expression in cancer cells, LINC01116 is markedly expressed in lymphatic endothelial cells of the tumor stroma in which it participates in hypoxia ...
Marine Gautier‐Isola +12 more
wiley +1 more source
Fly ash upcycling to functional silica nanomaterials: insights into synthetic strategies towards efficient adsorbents for water purification. [PDF]
Ruiz MS +3 more
europepmc +1 more source
THE CHEMISTRY OF COMBINED RESIDUAL CHLORINATION
Leao, S.F., Selleck, R.E.
openaire +1 more source
ATF4‐mediated stress response as a therapeutic vulnerability in chordoma
We screened 5 chordoma cell lines against 100+ inhibitors of epigenetic and metabolic pathways and kinases and identified halofuginone, a tRNA synthetase inhibitor. Mechanistically halofuginone induces an integrated stress response, with eIF2alpha phosphorylation, activation of ATF4 and its target genes CHOP, ASNS, INHBE leading to cell death ...
Lucia Cottone +11 more
wiley +1 more source
Building Trust: Validating Artificial Intelligence (AI) and Machine Learning in Agricultural Applications. [PDF]
Riter LS, Bienstock RJ, O'Sullivan W.
europepmc +1 more source
A subset of MMR‐proficient colon cancers responds to neoadjuvant immunotherapy
Tan et al. reveal that a distinct subset of early‐stage pMMR colon cancers can respond to neoadjuvant immunotherapy. In the NICHE‐2 trial, responders (26%) were characterized by chromosomal instability, TP53 mutations, and proliferative cell‐cycle programs, whereas nonresponders showed metabolic and stromal reprogramming with TGF‐β‐driven ...
Eleonora Piumatti +3 more
wiley +1 more source

